Photo courtesy of Klinik Pintar

照片由Klinik Smart提供

Klinik Pintar scores $5M to develop 'hybrid' clinic solution

Klinik Pintar获得500万美元开发“混合”诊所解决方案

Jakarta-based digital clinic network Klinik Pintar has raised $5 million in an extended Series A funding round led by Altara Ventures.

总部位于雅加达的数字诊所网络Klinik Pintar在Altara Ventures领导的A系列融资回合中筹集了500万美元。

Formerly Medigo, the company offers various clinical services, including teleconsultation and home health services. It runs a tech-enabled network of 22 primary, specialty, and corporate clinics.

该公司前身为Medigo，提供各种临床服务，包括远程会诊和家庭健康服务。它运营着一个由22家初级、专科和公司诊所组成的技术支持网络。

Klinik Pintar plans to use its new funds to expand its network and introduce new products. It is now preparing to launch a second neurology specialist clinic by yearend. It also recently entered into corporate care, launching over 12 on-site clinics with an automotive manufacturer. Moreover, it is trying to combine its SaaS and physical IT models to offer a new hybrid offering. .

Klinik Pintar计划利用其新资金扩大其网络并推出新产品。它现在正准备在年底前推出第二家神经病学专科诊所。它最近还进入了企业护理，与一家汽车制造商合作推出了12多家现场诊所。此外，它正在尝试将其SaaS和物理it模型相结合，以提供新的混合产品。。

BetterSpace gets pre-seed to develop mental health games

BetterSpace获得开发心理健康游戏的种子

Mental health tech startup BetterSpace has received $54,000 in pre-seed funding from PedalStart.

心理健康科技初创公司BetterSpace从PedalStart获得了5.4万美元的种子前资金。

Established in 2022, the startup provides counselling, workshops, and community engagement programmes around mental health.

这家初创公司成立于2022年，围绕心理健康提供咨询、研讨会和社区参与计划。

It will use its fresh funds to develop new products, including games and toolkits, boost marketing visibility, and optimise its app for greater accessibility across devices, among other uses.

它将利用其新资金开发新产品，包括游戏和工具包，提高市场知名度，并优化其应用程序，以提高跨设备的可访问性以及其他用途。

Another US FDA breakthrough designation for AWAK's predictive AI

AWAK预测AI的另一项美国FDA突破性指定

Singapore-based medtech AWAK Technologies has obtained its second breakthrough device designation from the United States Food and Drug Administration for its predictive AI.

总部位于新加坡的medtech AWAK Technologies因其预测性AI获得了美国食品和药物管理局的第二个突破性设备称号。

Its kidney disease progression prediction (KDPP) AI model assists with assessing the risk of kidney disease progression and the initiation of renal replacement therapy. The model was developed in collaboration with Ever Fortune.AI, a spin-off of China Medical University Hospital.

其肾脏疾病进展预测（KDPP）AI模型有助于评估肾脏疾病进展的风险和开始肾脏替代治疗。该模型是与Ever Fortune合作开发的。中国医科大学附属医院。

The FDA designation is AWAK's second, following that for its peritoneal dialysis device in 2019.

美国食品和药物管理局（FDA）是AWAK的第二个指定，仅次于2019年的腹膜透析装置。

AWAK will be collaborating with Singapore General Hospital to test its KDPP model using the hospital's de-identified data of chronic kidney disease patients. It is also in advanced talks to integrate its solutions with US partners.

AWAK将与新加坡综合医院合作，使用该医院的慢性肾脏病患者的未识别数据测试其KDPP模型。它还在与美国合作伙伴进行高级谈判，以整合其解决方案。

Tags: Klinik Pintar, Indonesia, BetterSpace, India, AWAK, Singapore

标签：Klinik Pintar，印度尼西亚，BetterSpace，印度，AWAK，新加坡

More regional news

更多地区新闻

Doctor Anywhere bags $41M, looks to enter genAI gameBy Adam AngDecember 06, 2023

《Anywhere医生》（Doctor Anywhere）包了4100万美元，有望进入genAI gameBy Adam Ang2023年12月6日

How people with hearing difficulties found support from a ChatGPT-powered business record-keeping toolBy Adam AngDecember 04, 2023

听力障碍患者如何从ChatGPT支持的商业记录保存工具中获得支持

Neurophet gears for 2024 IPO after $15M Series C raise and more digital health fundingsBy Adam AngNovember 17, 2023

AdamAng2023年11月17日，在C系列融资1500万美元和更多数字健康基金之后，Neurophet为2024年IPO做好了准备